A Double-Blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization
The purpose of this research study is to look at the changes in the fatty deposits in the walls of the blood vessels of the heart and blood levels of “good” and “bad” cholesterol when AMG 145, an investigational drug, is taken in addition to current medical therapy including “statins,” which are medications for the treatment of abnormal cholesterol blood levels. Participants in this study are undergoing coronary catheterization. In this study, the effects of AMG 145 will be determined by an intravascular ultrasound (IVUS) procedure that measures the amount of fatty deposits in the arteries of your heart.
Back to Clinical Trials list